GIST in Medical Technology

Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study

- Gleevec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST) EAST HANOVER, N.J., April 12, 2007 /PRNewswire/ -- Investigators will begin offering Gleevec(R) (imatinib mesylate)* tablets to patients receiving placebo in a ...

Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study

* Glivec found to dramatically reduce the risk of cancer returning after surgery for Kit-positive gastrointestinal stromal tumors (GIST) * Patients receiving placebo in this trial will now be offered Glivec * Global regulatory submissions planned for use of Glivec as adjuvant therapy in GIST p...

Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting

Data From the Companies' Novel Heat Shock Protein 90 Inhibitor Reveal Further Evidence of Safety, Tolerability, and Biological Activity CAMBRIDGE, Mass. and GAITHERSBURG, Md., June 5, 2007 (PRIME NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) and MedImmune, Inc. (Nasdaq:MEDI) today an...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

...tinually grow and divide. Similar KIT mutations in gist were shown to be treated effectively by Gleevec. T...th Ph+ CML and for adverse reactions in 5% of KIT+ gist patients. None of the 5 patients in the ASM study ...patients with severe hepatic impairment. Some gist patients (5%) were reported to have severe gastroi...

Glivec(R) is the First Adjuvant Treatment Approved in the UK to Delay Return of Gastrointestinal Cancer After Surgery

...vec daily for a year after surgery to remove their gist did not experience their tumours returning after 1...t population addresses a previously unmet need for gist patients. Roger Wilson, of patient group Sarcoma UK said: "After gist surgery, patients have to live with the knowledge ...

Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology

...ation in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocellular carcinoma, soft tissue sarcoma, gist tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

...ded dose should be used for patients with severe hepatic impairment. Some gist patients (5%) were reported to have severe gastrointestinal (GI) bleeds and...anorexia (17% each). The majority of patients who received Gleevec in the gist study experienced adverse reactions at some time. Most adverse reactions we...

Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology

...zation in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocellular carcinoma, soft tissue sarcoma, gist tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Di...

Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois

...zation in a variety of tumor types. KRX-0401 has shown single agent partial responses in renal cell and hepatocellular carcinoma, soft tissue sarcoma, gist tumors, mesothelioma, and carcinoma of the appendix. There is also evidence of activity in hematological malignancies, especially multiple myeloma. Di...

Launch of Highly Targeted Cancer Treatment Tasigna(R) (nilotinib) Offers Potential Lifeline to Ph+ CML Patients Intolerant or Resistant to Existing Therapies, Including Glivec(R) (imatinib)

...ic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL and on objective response rates in gist and DFSP. About Novartis Novartis AG (NYSE: NVS ) is a world leader in offering medicines to protect health, cure disease and improve well-being....

Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO

...cancers that are resistant to other drugs. About gist and Hsp90 The American Cancer Society (ACS) reports that gist is the most frequent form of gastrointestinal sarc...tes that between 4,500 and 6,000 Americans develop gist each year. In the majority of...